DDInter344 DDInter298
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and homeostasis. EGFR has been implicated in various types of cancer, as it is often overexpressed in malignant cells and EGFR overexpression has been linked to more advanced disease and poor prognosis. EGFR is often mutated in certain types of cancer and serves as a driver of tumorigenesis. _In vitro_, cetuximab was shown to mediate anti-tumour effects in numerous cancer cell lines and human tumour xenografts. Approved by the FDA in February 2004 under the brand name
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lansoprazole
Lansoprazole {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capecitabine
Capecitabine {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lansoprazole
Lansoprazole {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) palliates {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Cetuximab {u} may lead to a major life threatening interaction when taken with {v} Aminolevulinic acid
Aminolevulinic acid {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Oxaliplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Carboplatin
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Carboplatin (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Carboplatin (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Carboplatin (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) palliates esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Cetuximab may lead to a major life threatening interaction when taken with Aminolevulinic acid and Aminolevulinic acid (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Carboplatin (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Carboplatin (Compound)